← Mechanisms of action
CD19
SINGLE PROTEINHomo sapiens
Preferred name: B-lymphocyte antigen CD19 ChEMBL ↗
Linked proteins
Drugs acting on this target (250)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| tafasitamab (Monjuvi) | Adcc | approved | mAb | CD19 |
| vb119 | Adcc | experimental | mAb | CD19 |
| abo2203 | Binding agent | experimental | mAb | CD19 binding agent |
| axicabtagene ciloleucel (Yescarta) | Binding agent | approved | Cell therapy | B-lymphocyte antigen CD19 binding agent |
| B43-PAP | Binding agent | experimental | mAb | CD19 |
| bite-ev | Binding agent | experimental | mAb | CD19 binding agent |
| blinatumomab (blincyto) | Binding agent | approved | mAb | CD19 binding agent |
| Brexucabtagene autoleucel (Tecartus) | Binding agent | approved | Cell therapy | CD19 |
| caba-201 | Binding agent | experimental | Recombinant protein | CD19 binding agent |
| cc312 | Binding agent | experimental | mAb | CD19 binding agent |
| cln-978 | Binding agent | experimental | mAb | CD19 binding agent |
| coltuximab ravtansine | Binding agent | experimental | mAb | CD19 binding agent |
| depatuxizumab mafodotin | Binding agent | experimental | mAb | CD19 binding agent |
| gcc19cart | Binding agent | experimental | Cell therapy | CD19 |
| glpg5101 | Binding agent | experimental | Cell therapy | CD19 binding agent |
| gnc-038 | Binding agent | experimental | mAb | CD19 |
| iks03 | Binding agent | experimental | mAb | CD19 |
| inebilizumab (Uplizna) | Binding agent | approved | mAb | B-lymphocyte antigen CD19 binding agent |
| lisocabtagene maraleucel (Breyanzi) | Binding agent | approved | Cell therapy | CD19 binding agent |
| loncastuximab (Zynlonta) | Binding agent | approved | mAb | B-lymphocyte antigen CD19 binding agent |
| mdx 1342 | Binding agent | experimental | mAb | B-lymphocyte antigen CD19 binding agent |
| obecabtagene autoleucel | Binding agent | approved | Cell therapy | B-lymphocyte antigen CD19 binding agent |
| Obexelimab | Binding agent | experimental | mAb | B-lymphocyte antigen CD19 binding agent |
| oncolysin b | Binding agent | experimental | mAb | CD19 binding agent |
| pit565 | Binding agent | experimental | Small molecule | CD19 binding agent |
| shr1 | Binding agent | experimental | mAb | CD19 |
| snuh-cd19-car-t | Binding agent | experimental | Cell therapy | CD19 |
| tafasitamab (Monjuvi) | Binding agent | approved | mAb | B-lymphocyte antigen CD19 binding agent |
| taplitumomab paptox | Binding agent | experimental | mAb | CD19 binding agent |
| tisagenlecleucel (Kymriah) | Binding agent | approved | Cell therapy | B-lymphocyte antigen CD19 binding agent |
| TNB-486 | Binding agent | experimental | mAb | CD19 |
| yk012 | Binding agent | experimental | mAb | CD19 binding agent |
| blinatumomab (blincyto) | Cross-linking agent | approved | mAb | B-lymphocyte antigen CD19 cross-linking agent |
| mdx 1342 | Cross-linking agent | experimental | mAb | CD19 cross-linking agent |
| t-cell antigen presenting cells expressing truncated cd19 | Immunity, active | experimental | Vaccine | CD19 immunity, active |
| 19-28z t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| 1928t2z car-t cell | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| 4scar19 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| afm11 | Immunity, passive | experimental | mAb | CD19 immunity, passive |
| aleta-001 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| allo-329 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| allo-501 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| allogeneic car19 regulatory t cells (car19-ttreg) | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| allogeneic cd19 car-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| allogeneic donor-derived t-cells transduced with bivalent lentiviral vector (cd19/cd22-bbz) chimeric antigen receptor (car) | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| allogenic cd19-car-γδt cell | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| anbalcabtagene autoleucel | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| anti-cd19 and anti-cd20 bicistronic car t- cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| anti-cd19 fast car-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| anti-cd19 il10 car-nk | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| anti-cd19 ucar-nk cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| anti-cd19-car cmv-specific t-lymphocytes | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| anti-cd19-car gamma-delta t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| anti-cd19/20-car vector-transduced t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| anti-cd19/cd20/cd22 car t-cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| ari-0001 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| ari0003 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| arm011 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| ata3219 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| autologous anti-psca-car-4-1bb/tcrzeta-cd19t-expressing t-lymphocytes | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| autologous cd19 car+ egftt + t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| autologous cd19-star-t cell | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| autologous cd19/cd22 car t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| autologous cd19/cd22 chimeric antigen receptor t-cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| autologous humanized anti-cd19 and anti-cd20 dual specific car-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| autologous tricar t-cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| azercabtagene zapreleucel | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| b019 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| bcma/cd19 dual-target car-t | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| bi-4scar cd19/22 t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| bi-4scar cd19/70 t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| bi-4scar cd19/79b t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| bind19 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| bms-986515 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| bpx-501 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| c-car011 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| c402-cd19-car | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| c752 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cab-201 | Immunity, passive | experimental | Small molecule | unclear |
| car-20/19-t | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| car-t targeted cd19/cd20/cd22/cd30 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| car19 t cells carrying cytoplasmic activated pd-1 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| car20.19.22 cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| car2219-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| carcik-cd19 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cat19t2 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cb dualcar-nk19/70 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cb-010 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cb-10-01 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cc-97540 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19 allo-car-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19 car and pd-1 knock out engineered t-cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19 car-dc | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19 car-nk cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19 car-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19 t-hank | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19 universal car-γδ t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| CD19-7×19 CAR-T cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19-car_lenti t cell | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19-car_lenti_allo | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19-car-dnt cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19-car-t2 cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19-cd34 car transduced t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19-il7ra car-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19-pd1-cart cell | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19-targeted non-viral pd1 site-specific integrated car-t cell injection | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19-tricar-silk | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19-tricar-t | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19.car-ankt cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19.car-cd28z t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19/bcma hi-tcr-t cell | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19/cd20 bispecific car-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19/cd20/bcma car t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19/cd22-dual-star-t | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd19car-cd3zeta-4-1bb-expressing allogeneic t-lymphocyte cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cd28-cd3zeta-cd19t-expressing car t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cf33-cd19 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| chemokine (c-c motif) ligand 19-expressing cd19-car-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| clic-1901 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cnct19 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cnct19 car-t cell | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cnty-101 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cptx2309 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| ct-rd06 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cta30x | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| cta30x ucar-t | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| ctx110 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| ctx112 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| ctx131 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| decitabine-primed tandem car19/20 engineered t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| eb103 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| et019003-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| et190l1 artemis™ t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| exp039 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| ft522 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| ft596 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| gb5005 cart | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| gc007f | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| gc012f | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| gprc5d-cd19 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| gt719 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| hcd19.il15.car-inkt | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| human cd19 targeted dash car-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| humanized cd19 car-t cells with crs suppression technology | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| hy004 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| ic9-car19 cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| ic9/car.19/il15-transduced cb-nk cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| icar19 car-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| il-2 pre-treated cd19 cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| il-7/il-15 pre-treated cd19 cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells (Biological) | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| il13ralpha2-specific hinge-optimized 41bb-co-stimulatory car truncated cd19-expressing autologous t-lymphocytes | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| il13ralpha2-specific, hinge-optimized, 41bb-costimulatory car/truncated cd19-expressing autologous t lymphocytes | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| im19 car-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| imj995 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| impt-314 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| ins19 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| jcar015 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| jcar017 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| jwcar201 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| jwcar239 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| kcat19 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| kite-363 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| kn5601 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| kq-2003 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| kyv-101 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| kyv101 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| l218car19 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| lcar-aio cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| lstcar019 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| lucar-e9d | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| lucar-g39d | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| lv20.19 car t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| mc-1-50 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| mc-19pd1 car-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| mcd19-car-cd28-cd3-zeta | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| mov19-bbz car t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| murine cd19 car-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| musk-caart | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| neuk203-215 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| obecabtagene autoleucel | Immunity, passive | approved | Cell therapy | CD19 immunity, passive |
| p-cd19cd20-allo1 cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| pbcar19b | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| pbltt52car19 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| pcar-019 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| prg-2311 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| qn-019a | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| rc19d2 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| rd06-05 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| relma-cel | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| rpm cd19-mbil15-car-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| sc291 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| scri-car19v3 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| scri-hucar19v1 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| sscart-19 cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| str-p004 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| syncar-001 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| synkir-310 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| sz003 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| tac01-cd19 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| tak-007 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| tarcidomgen kimleucel | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| tbi-1501 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| tbi-2001 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| tc-110 t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| tcr reserved and power3 gene knock-out allogeneic cd19-targeting car-t cell | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| thiscart19 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| tmhucart19-il18 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| trac and power3 genes knock-out allogeneic cd19-targeting car-t cell (Athena Car-T) | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| ub-vv111 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| ub-vv400 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| uf-kure19 car-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| universal dual specificity cd19 and cd20 or cd22 car-t cells | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| utaa09 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| utaa91 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| uwd-19 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| welgenaleucel | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| XLCART001 | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| xyf19 car-t cell | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| zamtocabtagene autoleucel | Immunity, passive | experimental | Cell therapy | CD19 immunity, passive |
| 4g7xh22 | Inhibitor | experimental | mAb | CD19 inhibitor |
| A-319 | Inhibitor | experimental | mAb | CD19 inhibitor |
| amg 562 | Inhibitor | experimental | mAb | CD19 inhibitor |
| b43-genistein immunoconjugate | Inhibitor | experimental | mAb | CD19 inhibitor |
| coltuximab ravtansine | Inhibitor | experimental | mAb | CD19 inhibitor |
| deglycosylated ricin a chain-conjugated anti-cd19/anti-cd22 immunotoxins | Inhibitor | experimental | mAb | CD19 inhibitor |
| di-b4 | Inhibitor | experimental | mAb | CD19 inhibitor |
| dt2219arl | Inhibitor | experimental | mAb | CD19 inhibitor |
| duvortuxizumab | Inhibitor | experimental | mAb | CD19 inhibitor |
| gnr-084 | Inhibitor | experimental | mAb | CD19 inhibitor |
| iaso-782 | Inhibitor | experimental | mAb | CD19 inhibitor |
| inebilizumab (Uplizna) | Inhibitor | approved | mAb | CD19 inhibitor |
| ipm514 | Inhibitor | experimental | mAb | CD19 inhibitor |
| loncastuximab (Zynlonta) | Inhibitor | approved | mAb | CD19 inhibitor |
| ly3541860 | Inhibitor | experimental | mAb | CD19 inhibitor |
| mdx 1342 | Inhibitor | experimental | mAb | CD19 inhibitor |
| monoclonal antibody cd19 | Inhibitor | experimental | mAb | CD19 inhibitor |
| Obexelimab | Inhibitor | experimental | mAb | CD19 inhibitor |
| oncolysin b | Inhibitor | experimental | mAb | CD19 inhibitor |
| prizloncabtagene autoleucel | Inhibitor | experimental | Cell therapy | CD19 inhibitor |
| rn1101 | Inhibitor | experimental | mAb | CD19 inhibitor |
| ro7227166 | Inhibitor | experimental | mAb | CD19 inhibitor |
| swi019 | Inhibitor | experimental | mAb | CD19 inhibitor |
| taplitumomab paptox | Inhibitor | experimental | mAb | CD19 inhibitor |
| tg-1801 | Inhibitor | experimental | mAb | CD19 inhibitor |
| vnx-101 | Inhibitor | experimental | Gene therapy | CD19 inhibitor |
| xmab5574 | Inhibitor | experimental | mAb | CD19 inhibitor |
| y90 anti-cd19 monoclonal antibody bu12 | Inhibitor | experimental | mAb | CD19 inhibitor |
| inebilizumab (Uplizna) | Other | approved | mAb | CD19 other |
| 111in-bu-12 | Radiodepletion | experimental | mAb | CD19 radiodepletion |